Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design

Background: Development of countermeasures to bioterrorist threats such as those posed by the smallpox virus (variola), include vaccination and drug development. Selective activation of nucleoside analogues by virus-encoded thymidine (dThd) kinases (TK) represents one of the most successful strategi...

Full description

Bibliographic Details
Main Authors: El Omari, K, Solaroli, N, Karlsson, A, Balzarini, J, Stammers, D
Format: Journal article
Language:English
Published: BioMed Central 2006
Subjects:
_version_ 1797060657652170752
author El Omari, K
Solaroli, N
Karlsson, A
Balzarini, J
Stammers, D
author_facet El Omari, K
Solaroli, N
Karlsson, A
Balzarini, J
Stammers, D
author_sort El Omari, K
collection OXFORD
description Background: Development of countermeasures to bioterrorist threats such as those posed by the smallpox virus (variola), include vaccination and drug development. Selective activation of nucleoside analogues by virus-encoded thymidine (dThd) kinases (TK) represents one of the most successful strategies for antiviral chemotherapy as demonstrated for anti-herpes drugs. Vaccinia virus TK is a close orthologue of variola TK but also shares a relatively high sequence identity to human type 2 TK (hTK), thus achieving drug selectivity relative to the host enzyme is challenging. Results: In order to identify any differences compared to hTK that may be exploitable in drug design, we have determined the crystal structure of VVTK, in complex with thymidine 5'-triphosphate (dTTP). Although most of the active site residues are conserved between hTK and VVTK, we observe a difference in conformation of residues Asp-43 and Arg-45. The equivalent residues in hTK hydrogen bond to dTTP, whereas in subunit D of VVTK, Asp-43 and Arg-45 adopt a different conformation preventing interaction with this nucleotide. Asp-43 and Arg-45 are present in a flexible loop, which is disordered in subunits A, B and C. The observed difference in conformation and flexibility may also explain the ability of VVTK to phosphorylate (South)-methanocarbathymine whereas, in contrast, no substrate activity with hTK is reported for this compound. Conclusion: The difference in conformation for Asp-43 and Arg-45 could thus be used in drug design to generate VVTK/Variola TK-selective nucleoside analogue substrates and/or inhibitors that have lower affinity for hTK.
first_indexed 2024-03-06T20:20:12Z
format Journal article
id oxford-uuid:2d8b11cf-bfa8-47aa-aa61-17c44b8cdd66
institution University of Oxford
language English
last_indexed 2024-03-06T20:20:12Z
publishDate 2006
publisher BioMed Central
record_format dspace
spelling oxford-uuid:2d8b11cf-bfa8-47aa-aa61-17c44b8cdd662022-03-26T12:43:36ZStructure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug designJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2d8b11cf-bfa8-47aa-aa61-17c44b8cdd66Biology (medical sciences)EnglishOxford University Research Archive - ValetBioMed Central2006El Omari, KSolaroli, NKarlsson, ABalzarini, JStammers, DBackground: Development of countermeasures to bioterrorist threats such as those posed by the smallpox virus (variola), include vaccination and drug development. Selective activation of nucleoside analogues by virus-encoded thymidine (dThd) kinases (TK) represents one of the most successful strategies for antiviral chemotherapy as demonstrated for anti-herpes drugs. Vaccinia virus TK is a close orthologue of variola TK but also shares a relatively high sequence identity to human type 2 TK (hTK), thus achieving drug selectivity relative to the host enzyme is challenging. Results: In order to identify any differences compared to hTK that may be exploitable in drug design, we have determined the crystal structure of VVTK, in complex with thymidine 5'-triphosphate (dTTP). Although most of the active site residues are conserved between hTK and VVTK, we observe a difference in conformation of residues Asp-43 and Arg-45. The equivalent residues in hTK hydrogen bond to dTTP, whereas in subunit D of VVTK, Asp-43 and Arg-45 adopt a different conformation preventing interaction with this nucleotide. Asp-43 and Arg-45 are present in a flexible loop, which is disordered in subunits A, B and C. The observed difference in conformation and flexibility may also explain the ability of VVTK to phosphorylate (South)-methanocarbathymine whereas, in contrast, no substrate activity with hTK is reported for this compound. Conclusion: The difference in conformation for Asp-43 and Arg-45 could thus be used in drug design to generate VVTK/Variola TK-selective nucleoside analogue substrates and/or inhibitors that have lower affinity for hTK.
spellingShingle Biology (medical sciences)
El Omari, K
Solaroli, N
Karlsson, A
Balzarini, J
Stammers, D
Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design
title Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design
title_full Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design
title_fullStr Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design
title_full_unstemmed Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design
title_short Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design
title_sort structure of vaccinia virus thymidine kinase in complex with dttp insights for drug design
topic Biology (medical sciences)
work_keys_str_mv AT elomarik structureofvacciniavirusthymidinekinaseincomplexwithdttpinsightsfordrugdesign
AT solarolin structureofvacciniavirusthymidinekinaseincomplexwithdttpinsightsfordrugdesign
AT karlssona structureofvacciniavirusthymidinekinaseincomplexwithdttpinsightsfordrugdesign
AT balzarinij structureofvacciniavirusthymidinekinaseincomplexwithdttpinsightsfordrugdesign
AT stammersd structureofvacciniavirusthymidinekinaseincomplexwithdttpinsightsfordrugdesign